Calliditas Interim Report January to June 2024

Rhea-AI Summary

Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) released its interim report for January to June 2024. Key highlights include:

- Net sales for Q2 2024 reached SEK 559.8 million, with TARPEYO® sales at SEK 493.4 million.
- Adjusted operating profit for Q2 2024 was SEK 70.2 million, excluding expenses related to the Asahi Kasei offer and social security contributions.
- Cash position as of June 30, 2024, was SEK 797.3 million.
- Positive data from Nefecon Open Label Phase 3 Extension trial and setanaxib Phase 2 trial in head and neck cancer.
- Commercial launch of Nefecon in China by partner Everest Medicines.
- Full approval recommendation for Kinpeygo® in EU for IgA nephropathy treatment.
- Updated 2024 outlook: Total net sales from Nefecon franchise estimated at USD 165-185 million.

Positive

• Net sales increased to SEK 559.8 million in Q2 2024, up from SEK 269.4 million in Q2 2023
• TARPEYO® net sales grew to SEK 493.4 million in Q2 2024 from SEK 259.2 million in Q2 2023
• Adjusted operating profit of SEK 70.2 million for Q2 2024, compared to an operating loss in Q2 2023
• Positive data from Nefecon Open Label Phase 3 Extension trial and setanaxib Phase 2 trial in head and neck cancer
• Commercial launch of Nefecon in China by partner Everest Medicines
• Positive CHMP opinion recommending full approval for Kinpeygo® in EU for IgA nephropathy treatment
• New patent issued for setanaxib for cancer treatment, expiring in 2039
• Positive TRANSFORM Phase 2b topline data in primary biliary cholangitis
• Updated 2024 outlook: Total net sales from Nefecon franchise estimated at USD 165-185 million

Negative

• Operating loss of SEK 31.5 million in Q2 2024, though improved from SEK 75.2 million in Q2 2023
• Loss per share of SEK 0.88 in Q2 2024, improved from SEK 1.71 in Q2 2023 but still negative
• Cash position decreased to SEK 797.3 million as of June 30, 2024, from SEK 866.2 million in 2023

Insights

Financial Analyst

Calliditas' Q2 2024 results show significant progress, with net sales surging 107.8% year-over-year to SEK 559.8 million. TARPEYO, their key product, drove this growth with SEK 493.4 million in sales. The company's adjusted operating profit of SEK 70.2 million marks a turnaround from last year's loss, indicating improved operational efficiency.

However, investors should note the cash position decreased by 7.9% to SEK 797.3 million. This warrants attention to future cash flow management. The pending Asahi Kasei acquisition offer at SEK 208 per share represents a significant premium, potentially limiting near-term stock price upside.

The updated 2024 outlook projecting USD 165-185 million in Nefecon franchise sales demonstrates management's confidence in continued growth. Key catalysts include positive clinical trial results and expanded global commercialization, which could drive long-term value.

Medical Research Analyst

Calliditas' recent clinical developments are promising. The positive data from the Nefecon Open Label Phase 3 Extension trial reinforces the drug's efficacy in IgA nephropathy. Additionally, the successful Phase 2 trial of setanaxib in head and neck cancer expands the company's potential therapeutic reach.

The TRANSFORM Phase 2b topline data in primary biliary cholangitis further diversifies Calliditas' pipeline. These advancements, coupled with the new USPTO patent for setanaxib in cancer treatment (expiring 2039), strengthen the company's intellectual property position and potential market exclusivity.

The positive CHMP opinion and subsequent European Commission approval for Kinpeygo® in IgA nephropathy treatment expand the drug's market potential. This multi-pronged approach in rare diseases showcases Calliditas' strategic focus on high-value, unmet medical needs.

STOCKHOLM, Aug. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) :

April to June 2024 (compared to April to June 2023)

• Net sales amounted to SEK 559.8 million, of which TARPEYO^® net sales amounted to SEK 493.4 million, for the three months ended June 30, 2024. For the three months ended June 30, 2023, net sales amounted to SEK 269.4 million, of which TARPEYO net sales amounted to SEK 259.2 million.
• Operating loss amounted to SEK 31.5 million and SEK 75.2 million for the three months ended June 30, 2024, and 2023, respectively. However, expenses related to the Asahi Kasei offer and expenses related to provisions for social security contribution for incentive programs were included in the second quarter, totaling SEK 101.7 million. Excluding these expenses, the adjusted operating profit¹ amounted to SEK 70.2 million for the three months ended June 30, 2024.
• Loss per share before and after dilution amounted to SEK 0.88 and SEK 1.71 for the three months ended June 30, 2024, and 2023, respectively.
• Cash amounted to SEK 797.3 million and SEK 866.2 million as of June 30, 2024, and 2023, respectively.

January to June 2024 (compared to January to June 2023)

• Net sales amounted to SEK 855.3 million, of which TARPEYO^® net sales amounted to SEK 771.6 million, for the six months ended June 30, 2024. For the six months ended June 30, 2023, net sales amounted to SEK 460.7 million, of which TARPEYO net sales amounted to SEK 444.9 million.
• Operating loss amounted to SEK 235.3 million and SEK 255.2 million for the six months ended June 30, 2024, and 2023, respectively. However, expenses related to the Asahi Kasei offer and expenses related to provisions for social security contribution for incentive programs were included in the second quarter, totaling SEK 101.7 million. Excluding these expenses the adjusted operating loss¹ amounted to SEK 133.6 million for the six months ended June 30, 2024.
• Loss per share before and after dilution amounted to SEK 5.47 and SEK 5.21 for the six months ended June 30, 2024, and 2023, respectively.

Key takeaways from Q2, 2024

• In April, Calliditas read out positive data from the Nefecon Open Label Phase 3 Extension trial.
• In May, Calliditas read out positive topline results from the setanaxib Phase 2 trial in head and neck cancer.
• In May, Calliditas' partner Everest Medicines announced the commercial launch of Nefecon in China.
• In May, Calliditas' partner STADA received a positive CHMP opinion recommending full approval for Kinpeygo^® in EU for the treatment of IgA nephropathy.
• In June, Calliditas announced the issuance by the United States Patent and Trademark Office (USPTO) of a new patent for setanaxib for treatment of cancer. The patent will have an expiration date in 2039.

Key events after the reporting period

• In July, Calliditas partner STADA received European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy.
• In July, Calliditas announced positive TRANSFORM Phase 2b topline data in primary biliary cholangitis.

Asahi Kasei Offer

• Asahi Kasei Corporation announced on May 28, 2024, a public cash offer to acquire all shares in Calliditas for SEK 208 in cash per share (SEK 416 in cash per ADS). The Offer represents a premium of 83 per cent compared to the closing price of the Shares on Nasdaq Stockholm on May 27, 2024.
• The acceptance period of the offer commenced on July 18, 2024, and expires on August 30, 2024, subject to any extensions.

Outlook 2024: Updated

Calliditas expects continued revenue growth: Total net sales from the Nefecon franchise, including milestones, are estimated to be USD 165-185 million for the year ending December 31, 2024.

Investor Presentation

Today, 13 August at 2.30 p.m. CET

Link to webcast:
https://ir.financialhearings.com/calliditas-therapeutics-q2-report-2024

To participate via conference call register via this link:
https://conference.financialhearings.com/teleconference/?id=50049712

After registration, you will receive a phone number and a conference ID to log in to the conference call. There will be no Q&A following the presentation.   

For further information, please contact:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com

The information in the report is information that Calliditas is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Market Act. The information was sent for publication, through the agency of the contact person set out above, on August 13, 2024, at 7:00 a.m. CET.

¹Management uses and presents IFRS results as well as the non-IFRS measure of adjusted operating profit to evaluate and communicate its performance. While non-IFRS measures should not be construed as alternatives to IFRS measures, management believes non-IFRS measures are useful to further understand Calliditas's current performance, performance trends, and financial condition. Adjusted operating profit is defined as IFRS operating profit (loss), less provisions for social security contributions for incentive programs and advisor fees for the Asahi Kasei public offer. A reconciliation of adjusted operating profit to operating profit (loss), which is the most directly comparable IFRS measure, is set forth on page 31 of the attached report.

About Calliditas

Calliditas Therapeutics is a biopharma company headquartered in Stockholm, Sweden, focused on identifying, developing, and commercializing novel treatments in orphan indications with significant unmet medical needs. Calliditas' common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT). Visit Calliditas.com for further information.

Forward Looking Statements

This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Calliditas' strategy, business plans, revenue and other financial projections, and focus. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward looking statements contain these identifying words. Any forward-looking statements in this Press Release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this Press Release, including, without limitation, any related to Calliditas' business, operations, commercialization of TARPEYO, Kinpeygo and Nefecon, clinical trials, supply chain, strategy, goals and anticipated timelines for development and potential approvals, competition from other biopharmaceutical companies, revenue and product sales projections or forecasts, including 2024 total net sales guidance and cash runway, all statements regarding the public offer by Asahi Kasei Corporation, profitability and other risks identified in the section entitled "Risk Factors" in Calliditas' reports filed with the Securities and Exchange Commission. Calliditas cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Calliditas disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this Press Release represent Calliditas' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/calliditas-therapeutics/r/calliditas-interim-report-january-to-june-2024,c4023451

The following files are available for download:

https://mb.cision.com/Main/16574/4023451/2941204.pdf	Q2_2024_Calliditas_ ENG
https://mb.cision.com/Public/16574/4023451/9ab9f21fbc3f536c.pdf	PR Q2 ENG final

 

View original content:https://www.prnewswire.com/news-releases/calliditas-interim-report-january-to-june-2024-302220664.html

SOURCE Calliditas Therapeutics

FAQ

What were Calliditas Therapeutics' (CALT) net sales for Q2 2024?

Calliditas Therapeutics' net sales for Q2 2024 amounted to SEK 559.8 million, of which TARPEYO® net sales were SEK 493.4 million.

How did Calliditas' (CALT) Q2 2024 financial results compare to Q2 2023?

Net sales increased significantly from SEK 269.4 million in Q2 2023 to SEK 559.8 million in Q2 2024. The operating loss improved from SEK 75.2 million to SEK 31.5 million.

What is Calliditas Therapeutics' (CALT) updated revenue outlook for 2024?

Calliditas expects total net sales from the Nefecon franchise, including milestones, to be USD 165-185 million for the year ending December 31, 2024.

What significant clinical trial results did Calliditas (CALT) report in Q2 2024?

Calliditas reported positive data from the Nefecon Open Label Phase 3 Extension trial and positive topline results from the setanaxib Phase 2 trial in head and neck cancer.